Free tool
FAERS Monitor: Nuvigil
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 021875 or its brand name (Nuvigil, Armodafinil). Reports on generic versions are filed under their own applications.
Reports
21,062
Serious
9,699
46% of reports
Hospitalization
2,559
Death reported
326
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- drug ineffective1,579
- fatigue1,525
- nausea1,487
- headache1,411
- anxiety1,187
- somnolence1,110
- depression1,021
- insomnia986
- feeling abnormal961
- fall897
- dizziness880
- weight decreased748
- pain716
- condition aggravated701
- sleep apnoea syndrome629
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2008 | 4 |
| 2009 | 59 |
| 2010 | 202 |
| 2011 | 445 |
| 2012 | 2,692 |
| 2013 | 763 |
| 2014 | 820 |
| 2015 | 2,028 |
| 2016 | 5,261 |
| 2017 | 1,670 |
| 2018 | 1,525 |
| 2019 | 1,432 |
| 2020 | 1,044 |
| 2021 | 540 |
| 2022 | 622 |
| 2023 | 681 |
| 2024 | 612 |
| 2025 | 399 |
| 2026 | 263 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,033,097 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| sleep apnoea syndromeSignal | 629 | 34.0 | 31.4 | 19,470 |
| somnolenceSignal | 1,110 | 5.5 | 5.2 | 4,131 |
| depressionSignal | 1,021 | 4.5 | 4.2 | 2,791 |
| anxietySignal | 1,187 | 4.2 | 4.0 | 2,894 |
| feeling abnormalSignal | 961 | 4.0 | 3.8 | 2,191 |
| insomniaSignal | 986 | 3.7 | 3.5 | 1,964 |
| fallSignal | 897 | 2.7 | 2.5 | 968 |
| weight decreasedSignal | 748 | 2.7 | 2.5 | 795 |
| condition aggravatedSignal | 701 | 2.3 | 2.1 | 523 |
| headacheSignal | 1,411 | 2.3 | 2.1 | 1,007 |
| fatigue | 1,525 | 2.0 | 1.9 | 740 |
| nausea | 1,487 | 1.9 | 1.8 | 632 |
| dizziness | 880 | 1.8 | 1.7 | 296 |
| drug ineffective | 1,579 | 1.2 | 1.1 | 54 |
| pain | 716 | 1.2 | 1.1 | 17 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.